Private Advisor Group LLC bought a new position in Masimo Co. (NASDAQ:MASI – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 4,602 shares of the medical equipment provider’s stock, valued at approximately $849,000.
Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Masimo by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock worth $695,050,000 after purchasing an additional 71,918 shares during the period. State Street Corp increased its holdings in shares of Masimo by 1.6% during the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider’s stock worth $251,928,000 after purchasing an additional 27,261 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Masimo by 92.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 856,664 shares of the medical equipment provider’s stock worth $111,940,000 after purchasing an additional 410,793 shares during the period. Geode Capital Management LLC increased its holdings in shares of Masimo by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 703,196 shares of the medical equipment provider’s stock worth $103,920,000 after purchasing an additional 31,667 shares during the period. Finally, Schroder Investment Management Group increased its holdings in shares of Masimo by 44.9% during the 4th quarter. Schroder Investment Management Group now owns 577,277 shares of the medical equipment provider’s stock worth $85,408,000 after purchasing an additional 178,753 shares during the period. Institutional investors own 85.96% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently issued reports on MASI shares. Wells Fargo & Company dropped their price objective on shares of Masimo from $126.00 to $110.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 9th. StockNews.com lowered shares of Masimo from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Needham & Company LLC reiterated a “buy” rating and set a $136.00 target price on shares of Masimo in a research report on Wednesday, August 9th. Stifel Nicolaus lowered shares of Masimo from a “buy” rating to a “hold” rating and decreased their target price for the company from $205.00 to $120.00 in a research report on Tuesday, July 18th. Finally, Raymond James decreased their target price on shares of Masimo from $198.00 to $142.00 and set an “outperform” rating on the stock in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $151.33.
Masimo Price Performance
Shares of MASI stock opened at $114.62 on Wednesday. Masimo Co. has a 1 year low of $105.50 and a 1 year high of $198.00. The firm’s 50 day moving average is $131.49 and its 200-day moving average is $159.24. The firm has a market capitalization of $6.05 billion, a price-to-earnings ratio of 53.56 and a beta of 0.83. The company has a current ratio of 2.11, a quick ratio of 1.16 and a debt-to-equity ratio of 0.68.
Masimo (NASDAQ:MASI – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The medical equipment provider reported $0.62 earnings per share for the quarter, missing the consensus estimate of $0.86 by ($0.24). Masimo had a net margin of 5.30% and a return on equity of 15.79%. The company had revenue of $455.30 million during the quarter, compared to analyst estimates of $478.27 million. During the same quarter last year, the company earned $1.35 EPS. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. Sell-side analysts forecast that Masimo Co. will post 3.46 EPS for the current fiscal year.
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
- Five stocks we like better than Masimo
- Which Wall Street Analysts are the Most Accurate?
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- What Are Growth Stocks and Investing in Them
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- Energy and Oil Stocks Explained
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.